A phase 1 study of OSI-930 in combination with erlotinib in patients with advanced solid tumours
Introduction
Extensive cross-talk between the vascular endothelial growth factor (VEGF) and epidermal growth factor (EGF) receptor signalling pathways provides a rationale for combined inhibition of these receptor tyrosine kinases.1, 2, 3, 4, 5, 6, 7, 8 However, the results of recent phase III trials evaluating dual targeting of VEGF and EGFR signalling in colorectal cancer and non-small cell lung cancer (NSCLC) have been disappointing9, 10, 11, 12, 13, 14, 15 and the optimal agent, disease setting, and patient selection for this approach remain uncertain.
OSI-930 is a novel small molecule tyrosine kinase inhibitor with potent activity against vascular endothelial growth factor receptor 2 (VEGFR2)/kinase insert domain receptor (KDR), c-Kit and platelet-derived growth factor receptor (PDGFR).16, 17 Dose limiting toxicities for OSI-930 monotherapy included grade 3 rash, myalgia, fatigue, raised lipase and grade 4 raised gamma glutamyl transferase whilst common grade 1/2 toxicities included rash, fatigue, diarrhoea, nausea and anorexia.17 In preclinical studies the combination of OSI-930 and erlotinib, a selective EGFR kinase inhibitor, demonstrated enhanced efficacy compared to either agent alone.18 The primary objective of this study was therefore to determine the maximum tolerated dose (MTD) of OSI-930 that could be combined with erlotinib and to establish recommended doses of both agents when administered in combination.
Section snippets
Patients and eligibility criteria
This was a phase I, multi-centre dose-escalation study of OSI-930 and erlotinib, co-administered orally in patients with advanced solid tumours. The study was conducted in accordance with the principles of International conference on harmonisation good clinical practice (ICH GCP) and approved by the Research Ethics Committee at each institution.
Eligible patients had a pathologically confirmed advanced solid malignancy, refractory to conventional therapy; age ⩾18; life expectancy ⩾12 weeks;
Patient characteristics
Twenty-one patients were enrolled in three treatment cohorts (Table 1). One patient in cohort 2 experienced rapid disease progression and did not receive either study drug. The median duration of treatment was 77 (range 7–176) days with one patient continuing study treatment at the time of study data closure. Patient characteristics are summarised in Table 2.
Dose limiting toxicity
All 20 patients who received at least one dose of OSI-930 were evaluable for safety, whilst 18 patients were evaluable for dose-limiting
Discussion
Defining the MTD has been the standard approach for determining the recommended starting dose of a cytotoxic agent which is then usually administered intermittently and for a defined treatment course. However, cumulative toxicity is an important consideration in determining the recommended doses of agents that are administered in protracted oral daily schedules, often until disease progression. In this phase 1 trial DLTs included grade 4 neutropenia and grade 3 lethargy/asthenia, but no
Funding
This study was supported by OSI Pharmaceuticals LLC. The Glasgow Experimental Cancer Medicine Centre is supported by Cancer Research UK and by the Chief Scientist Office (Scotland).
Role of Funding Source
This study was sponsored and funded by OSI Pharmaceuticals LLC. The sponsor was involved in the design of the study and in the analysis and interpretation of data. Financial support to cover the cost of running the study was provided by OSI Pharmaceuticals LLC. The sponsor reviewed and contributed to the manuscript which was primarily written by I.M.
Conflict of interest statement
S. Poondru, R. Gedrich, K. Brock, and A. Stephens are current or previous employees of OSI Pharmaceuticals. R. Gedrich held stock in OSI Pharmaceuticals when the research was performed. T.R.J. Evans has received research funding from OSI Pharmaceuticals. All remaining authors have declared no conflicts of interest.
References (24)
- et al.
Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy (BeTa): a double-blind, placebo-controlled, phase 3 trial
Lancet
(2011) - et al.
Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial
Lancet Oncol
(2010) The role of VEGF and EGFR inhibition: implications for combining anti-VEGF and anti-EGFR agents
Mol Cancer Res
(2007)- et al.
Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors
Am J Pathol
(1997) - et al.
EGFR antisense treatment of human HNSCC cell lines down-regulates VEGF expression and endothelial cell migration
Int J Oncol
(2002) - et al.
Acquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies in vivo: a role for altered tumor angiogenesis
Cancer Res
(2001) - et al.
Antitumor activity of ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in human cancer cells with acquired resistance to antiepidermal growth factor receptor therapy
Clin Cancer Res
(2004) - et al.
Vascular endothelial growth factor receptor-1 contributes to resistance to anti-epidermal growth factor receptor drugs in human cancer cells
Clin Cancer Res
(2008) - et al.
Combined vascular endothelial growth factor receptor and epidermal growth factor receptor (EGFR) blockade inhibits tumor growth in xenograft models of EGFR inhibitor resistance
Clin Cancer Res
(2009) - et al.
Upregulated stromal EGFR and vascular remodeling in mouse xenograft models of angiogenesis inhibitor-resistant human lung adenocarcinoma
J Clin Invest
(2011)
Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer
N Engl J Med
A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer
J Clin Oncol
Cited by (6)
CSF1R inhibitors are emerging immunotherapeutic drugs for cancer treatment
2023, European Journal of Medicinal ChemistryCitation Excerpt :OSI-930 entered clinical in 2007 to study the safety of OSI-930 in patients with advanced solid tumors (NCT00513851). The results from phase I trials of OSI-930 solely or in combination with erlotinib have provided MTD and RP2D [107,108]. Antitumor responses were observed in two patients with advanced OC.
Coordination-driven self-assembly and anticancer studies of thiophene-derived donor and arene ruthenium acceptors
2018, Inorganica Chimica ActaDual roles of drug or its metabolite−protein conjugate: Cutting-edge strategy of drug discovery using shotgun proteomics
2022, Medicinal Research ReviewsRecent progress in the development of quinoline derivatives for the exploitation of anti-cancer agents
2021, Anti-Cancer Agents in Medicinal Chemistry